An eminent scientist talks about the pharmaceutical industry, biotechnology and the future of drug research. In the course of our busy, technologically-driven lives, it is taken for granted that we respond to minor fluctuations in our health by taking pills -- pills for headache and for toothache; sleeping pills and tranquilizers; pills to lower fever, quiet coughs, and clear the sinuses; medicines to reduce appetite; preparations to relieve heartburn; and many more. In the war against serious disease, medicines are an indispensable weapon in the physician's arsenal: they save lives, or at least prolong them and make them more bearable. Despite the important role that pharmaceuticals play in our lives, few of us know where medicines come from or how the pharmaceutical industry discovers and develops new drugs. Jurgen Drews, an acclaimed leader in the pharmaceutical industry, tells the fascinating story of drug discovery and development from his years of successfully leading internatnional research teams at Hoffman-LaRoche. Drews traces the history of modern drug development from pharmacies, chemical companies, and individual entrepeneurs in Switzerland, Germany and the U.S. to the mega-corporations that dot the landscape of Europe, Japan and America. He describes the process by which new drugs are tested and brought to market, including a provacative look at how AIDS activism stimulated the approval process in the US. Drews' commentary on the role of clinical trials -- the time involved and their cost -- is sobering testimony to the complexity of bringing innovation to the marketplace. In the final two chapters of "In Quest of Tomorrow's Medicines", Drews offers an important and critical analysis of research in the the pharmaceutical industry, pointing to strategies that work and management practices that impede progress. Drews' comments on the impact that the growing relationship between the biotechnology industry and university-sponsored research will have ont he pharmaceutical industry makes provocative reading for pharmaceutical researchers, managers and investors. "In Quest of Tomorrow's Medicines" in written in clear, thoughtful language for people in the pharmaceutical and biotechnology industries, as well as policy makers, industry analysts and observers.

The "First International Conference on Traditional Chinese Medicine: Science, Regulation and Globalization" was held from August 30 to September 2, 2000 at the University of Maryland at College Park, Maryland. There were approximately 250 participants from the Peoples Republic of China, Taiwan, Hong Kong and the United States. This objective of this conference was to promote international collaboration for the modernization of Traditional Chinese herbal medicines (TCM) and their introduction into the global health care system. It was mainly sponsored by the Ministry of Science and Technology of the People's Republic of China and the NllI National Center for Complementary and Alternative Medicine (NCCAM). It was organized by Dr. William Tai, then director of the Institute of Global Chinese Affairs at the University of Maryland and Dr. Yuan Lin, president of Marco Polo Technologies, Bethesda, MD. This conference was conceived by Dr. Tai two years earlier recognizing that this was an appropriate time and also the unique location of the University of Maryland. Today, there is a growing recognition of the of alternative medicine in modem societies and the rapid loss of importance knowledge about traditional methods for the treatment of the multitude of human illnesses found throughout the world. TCM has been in common use in China for thousands of years; and many of its formulations are well defined.

"Concise and easy to read, the book quickly introduces basic concepts, then moves on to discuss target selection and the drug discovery process for both small and large molecular drugs." —Doody's Reviews, May 2009 "The second edition of a book that offers a user-friendly step-by-step introduction to all the key processes involved in bringing a drug to the market, including the performance of preclinical trials." —Chemistry World, February 2009 The new edition of this best-selling book continues to offer a user-friendly, step-by-step introduction to all the key processes involved in bringing a drug to the market, including the performance of pre-clinical studies, the conduct of human clinical trials, regulatory controls, and even the manufacturing processes for pharmaceutical products. Concise and easy to read, the book quickly introduces basic concepts, then moves on to discuss target selection and the drug discovery process for both small and large molecular drugs. This second edition features many key enhancements, including Key Points, Chapter Summary, and Review Questions in each chapter, Answers to Review Questions provided in a book-end appendix, and one or two carefully selected "mini" case studies in each chapter. Richly illustrated throughout with over ninety figures and tables, this important book also includes helpful listings of current FDA and European guidelines and a special section on regulatory authority and processes in China. It is an indispensable resource for pharmaceutical industry and academic researchers, pharmaceutical managers and executives, healthcare clinicians, policymakers, regulators, and lobbyists with an interest in drug development. It is also an excellent textbook for students in pharmacy, science, and medicine courses.

Despite the pharmaceutical industry's notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Government officials and social critics have questioned whether the multibillion-dollar industry is fulfilling its social responsibilities. This doubt has been fueled by the national debate over drug pricing and affordable healthcare, and internationally by the battles against epidemic diseases, such as AIDS, in the developing world. Debates are raging over how the industry can and should be expected to act. The contributions in this book by leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, and marketing.

ContentsPreface and Acknowledgments PART I1 The History of the School 2 The Curriculum 3 The Graduate School of Biological Sciences PART II4 The Basic Sciences 5 The Centers and Institutes 6 The Department of Community and Preventive Medicine 7 The Department of Human Genetics 8 The Department of Health Policy 9 Graduate and Postgraduate Education Part III10 The Faculty Practice Plan 11 The Mount Sinai Alumni 12 Student Voices: In Their Own WordsAppendixes A. Saul Horowitz, Jr. Memorial Award Recipients B. Honorary Degree Recipients C. The Mount Sinai Leadership D. The Mount Sinai Boards of Trustees, 2003 Notes Index About the Authors

Drs. Greek have written 2 books on why using animals as models for humans is not the best way to conduct medical research and drug testing. During their lectures and debates, the most commonly asked question was, "Well. What will we use if we don't use animals?" What Will We Do If We Don't Experiment On Animals? Medical Research for the Twenty-first Century is the answer to that question. Drs. Greek explain briefly why one species cannot predict drug response for another and describe what research and testing methods should be used today instead of animals. They also describe where our biomedical research dollars should be spent if we are to have cures for cancer, AIDS, and Alzheimer's. This book will appeal to science-trained and general audiences, animal lovers and science readers, public policy analysts, students, patients and patient support groups, and government watchdog groups. What Will We Do If We Don't Experiment On Animals? Medical Research for the Twenty-first Century takes medical research out of the nineteenth and into the 21st century.